Business

MindRank's USD 52m Series B advances AI-designed GLP-1 into pivotal Phase III obesity trial

Edited by Robert McTiernan··2 min read
MindRank's USD 52m Series B advances AI-designed GLP-1 into pivotal Phase III obesity trial

China-based MindRank AI Ltd. has closed a USD 52 million Series B financing round to advance its AI-native drug discovery platform and clinical pipeline, including MDR-001, an oral small-molecule GLP-1 receptor agonist currently in Phase III development in China.

The round was led by a group of institutional and healthcare funds, which were not individually named in the announcement. Proceeds will support continued development of MindRank's proprietary Molecule Arts Platform (MAP) and the progression of its clinical and preclinical pipeline. No prior funding rounds were disclosed by the company.

MDR-001 is the company's lead asset and one of the more clinically advanced AI-designed small molecules in the GLP-1 space. The program entered Phase III in 2025 following initiation of the MOBILE pivotal trial, which is enrolling approximately 750 participants with overweight or obesity in China to evaluate 52-week efficacy and safety. Phase IIb data from 317 participants demonstrated a mean weight reduction of 10.3% at Week 24, with a treatment-emergent adverse event discontinuation rate of 0.8% — a profile the company has cited as indicative of best-in-class safety potential. Cardiometabolic improvements were also reported across hepatic function measures, uric acid, waist circumference, blood pressure, and lipid profiles.

MDR-001 progressed from project initiation to Phase III in approximately 4.5 years, with cumulative R&D investment through the start of Phase III estimated at approximately USD 23 million — a figure the company says reflects the capital efficiency of its AI-driven discovery platform..

Beyond MDR-001, MindRank has obtained three investigational new drug clearances in China and the US and has nominated five additional preclinical development candidates.

The AllSci BriefFree, systematic R&D and deal news. Daily.

MAP integrates multi-agent AI systems, generative molecular design, computational biology, experimental validation, and clinical learning within a unified platform. The system is designed to operate as a continuously learning R&D engine, with the stated goal of making drug discovery more predictable and scalable.

The oral small-molecule GLP-1 receptor agonist space is competitive and well-funded. Ambrosia Biosciences closed a USD 100 million Series B in Q1 2026 to advance its own oral small-molecule GLP-1 candidate toward Phase I. Metsera has also initiated clinical trials of an oral GLP-1 peptide program. MindRank's differentiation argument centers on MDR-001's biased-selective receptor agonism — the molecule is reported to promote cAMP signaling while also selectively recruiting beta-arrestin 2, a profile the company says produces metabolic benefits beyond weight loss, including uric acid reduction and hepatic function improvement, without increasing heart rate.

The financing is intended to support completion of the MOBILE Phase III trial and continued development of MindRank's broader pipeline. Topline data from the 52-week study will represent the next major clinical milestone for MDR-001.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article